[1] |
ZHANG C, LI D N, YU R X, et al. Immune landscape of gastric carcinoma tumor microenvironment identifies a peritoneal relapse relevant immune signature[J]. Front Immunol, 2021, 12: 651033.
doi: 10.3389/fimmu.2021.651033
|
[2] |
KANG Y K, CHIN K, CHUNG H C, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(8): 1045-1056.
doi: 10.1016/S1470-2045(20)30315-6
|
[3] |
皇甫娟, 张强, 魏祯瑶, 等. 基于p53介导自噬通路探讨臭椿酮对顺铂耐药胃癌细胞株耐药性的影响[J]. 现代药物与临床, 2021, 36(6): 1112-1118.
|
|
HUANGFU J, ZHANG Q, WEI Z Y, et al. Effect of ailanthone on cisplatin-resistant gastric cancer cell line based on p53-mediated autophagy pathway[J]. Drugs Clin, 2021, 36(6): 1112-1118.
|
[4] |
陈延群, 莫海云. DOF方案与XELOX方案一线治疗进展期胃癌疗效对比[J]. 中华肿瘤防治杂志, 2021, 28(10): 782-787.
|
|
CHEN Y Q, MO H Y. Comparison of DOF regimen and XELOX regimen as first-line treatment in advanced gastric cancer patients[J]. Chin J Cancer Prev Treat, 2021, 28(10): 782-787.
|
[5] |
SHITARA K, BANG Y J, IWASA S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J]. N Engl J Med, 2020, 382(25): 2419-2430.
doi: 10.1056/NEJMoa2004413
|
[6] |
JANJIGIAN Y Y, MARON S B, CHATILA W K, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(6): 821-831.
doi: S1470-2045(20)30169-8
pmid: 32437664
|
[7] |
中国研究型医院学会消化道肿瘤专业委员会, 中国医师协会外科医师分会多学科综合治疗专业委员会. 胃肠间质瘤多学科综合治疗协作组诊疗模式专家共识[J]. 中国实用外科杂志, 2017, 37(1): 39-41.
|
|
Digestive Tumor Professional Committee of China Research Hospital Association, Multidisciplinary Comprehensive Therapy Professional Committee of the Surgical Branch of the Chinese Medical Association. Expert consensus on diagnosis and treatment mode of gastric cancer multidisciplinary comprehensive treatment collaboration group[J]. Chin J Pract Surg, 2017, 37(1): 39-41.
|
[8] |
曹毛毛, 李贺, 孙殿钦, 等. 2000—2019年中国胃癌流行病学趋势分析[J]. 中华消化外科杂志, 2021, 20(1): 102-109.
|
|
CAO M M, LI H, SUN D Q, et al. Epidemiological trend analysis of gastric cancer in China from 2000 to 2019[J]. Chin J Dig Surg, 2021, 20(1): 102-109.
|
[9] |
LIOU J M, MALFERTHEINER P, LEE Y C, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus[J]. Gut, 2020, 69(12): 2093-2112.
doi: 10.1136/gutjnl-2020-322368
|
[10] |
张维汉, 杨昆, 陈心足, 等. 规范化外科手术与多学科综合治疗对胃癌患者预后的影响:一项单中心队列研究报告[J]. 中华胃肠外科杂志, 2020, 23(4): 396-404.
|
|
ZHANG W H, YANG K, CHEN X Z, et al. Effect of standardized surgical treatment and multidisciplinary treatment strategy on the prognosis of gastric cancer patients: report of a single-center cohort study.[J]. Chin J Gast S, 2020, 23(4):396-404.
|
[11] |
艾克热木·玉苏甫, 阿布都沙拉木·依米提, 再依奴尔·阿不都外力, 等. 不同新辅助化疗方案治疗进展期胃癌的疗效和安全性及费用评估研究[J]. 中国全科医学, 2020, 23(26): 3286-3290.
doi: 10.12114/j.issn.1007-9572.2019.00.774
|
|
AIKEREMU·YUSUFU, ABUDUSHALAMU·YIMITI, ZAIYINUER·ABUDUWAILI, et al. Evaluation of safety, efficacy and hospitalization cost of three neoadjuvant chemotherapy regimens for advanced gastric cancer[J]. Chin Gen Pract, 2020, 23(26): 3286-3290.
|
[12] |
MAKIYAMA A, SUKAWA Y, KASHIWADA T, et al. Randomized, phase Ⅱ study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study)[J]. J Clin Oncol, 2020, 38(17): 1919-1927.
doi: 10.1200/JCO.19.03077
|
[13] |
HACKSHAW M D, BUI C L, LADNER A, et al. Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumab[J]. Cancer Treat Res Commun, 2020, 24: 100189.
|
[14] |
朱麒, 肖瑶, 金丽艳, 等. 曲妥珠单抗联合化疗对HER-2阳性胃癌患者T淋巴细胞亚群及肿瘤标志物的影响[J]. 临床肿瘤学杂志, 2023, 28(2): 159-163.
|
|
ZHU Q, XIAO Y, JIN L Y, et al. Effects of Trastuzumab combined with chemotherapy on T lymphocyte subsets and tumor markers in patients with HER-2 positive gastric cancer[J]. Chin Clin Oncol, 2023, 28(2): 159-163.
|
[15] |
李红, 史长山. 曲妥珠单抗辅助治疗HER2阳性晚期胃癌的安全性及对患者血清肿瘤标志物的影响研究[J]. 长春中医药大学学报, 2022, 38(1): 88-92.
|
|
LI H, SHI C S. Safety of the trastuzumab adjuvant treatment of HER2-positive advanced gastric cancer and its effect on patients' serum tumor markers[J]. J Changchun Univ Chin Med, 2022, 38(1): 88-92.
|